No-Cell-Collection CAR-T: new shot at blood cancer remission?

NCT ID NCT07485504

Not yet recruiting Disease control Sponsor: Tcelltech Inc. Source: ClinicalTrials.gov ↗

First seen Mar 28, 2026 · Last updated May 24, 2026 · Updated 7 times

Summary

This early study tests a new treatment called DIT101 for people with blood cancers that have come back or stopped responding to standard therapy. DIT101 is a type of CAR-T therapy that works inside the body, so patients don't need to have their cells collected and modified in a lab. The study will check if DIT101 is safe and whether it can shrink tumors, with about 15 adults taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)

Tianjin, China

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES